Basic Search  |  Summaries  |  Advanced Search

Violation Tracker Individual Record

Company: Mylan Inc.
Current Parent Company: Viatris
Penalty: $96,525,000
Year: 2018
Date: May 7, 2018
Offense Group: competition-related offenses
Primary Offense: price-fixing or anti-competitive practices
Secondary Offense: generic drug pay for delay
Mega-Scandal: Generic Drug Pay for Delay
Violation Description: Mylan agreed to pay over $96 million to direct purchaser plaintiffs to settle litigation alleging it participated in an arrangement to delay the introduction of a generic version of the narcolepsy drug Provigil.
Level of Government: federal
Action Type: private litigation
Court: Eastern District of Pennsylvania
Civil or Criminal Case: civil
Case ID: 2:06cv1797
Case Name: King Drug Company of Florence, Inc vs. Cephalon, Inc., et al
Private Lawsuit Resolution Type: settlement
HQ Country of Current Parent: USA
HQ State of Current Parent: Pennsylvania
Ownership Structure of Current Parent: publicly traded
Major Industry of Current Parent: pharmaceuticals
Specific Industry of Current Parent: pharmaceuticals
Source of Data: (click here)
Link to PACER Case Docket (must be logged in): (click here)
Link to Archived Court Document:  subscribe to see this data field
Source Notes: If an online information source is not working, check the Violation Tracker Data Sources page for an updated link.
Current parent company note: Parent-subsidiary relationship is current as of the most recent revision listed in the Update Log.